Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

Cancer

Volumn 89, Issue 1, 2000, Pages 74-82

  Overholser, Jay P ^a   Prewett, Marie C ^a   Hooper, Andrea T ^a   Waksal, Harlan W ^a   Hicklin, Daniel J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 fluorouracil; Epidermal growth factor receptor; Monoclonal antibody; Pancreatic carcinoma; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TUMOR NECROSIS; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; DNA, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LIGANDS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034235955     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K     Document Type: Article

References (55)

1. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Front Biosci 1998;3:E214-5.
2. Jeekel J. Adjuvant or neoadjuvant therapy for pancreatic carcinoma? Digestion 1997;58:533-5.
3. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
4. Carmichael J. Clinical response benefit in patients with advanced pancreatic cancer - role of gemcitabine. Digestion 1997;58:503-7.
5. Longnecker DS. Hormones and receptors in gastrointestinal malignancies. Digestion 1990;46(2 Suppl):92-8.
6. Kroc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl. Acad Sci USA 1986;83:5141-4.
7. Smith JJ, Derynck R, Korc M. Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 1987;84:7567-70.
8. Chen YF, Pan GZ, Hou X, Liu TH, Chen J, Yanaihara C, et al. Epidermal growth factor and its receptors in human pancreatic carcinoma. Pancreas 1990;5:278-83.
9. Beauchamp RD, Lyons RM, Yang EY, Coffey RJ Jr., Moses HL. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 1990;5:369-80.
10. Bleday R, Tzanakakis GN, Schwalke MA, Wanebo HJ, Vezeridis MP. Epidermal growth factor stimulation and metastatic rate in human pancreatic carcinoma cell lines. J Surg Res 1990;49:276-9.
11. Ohmura E, Tsushima T, Kamiya Y, Okada M, Onoda N, Shizume K, et al. Epidermal growth factor and transforming growth factor alpha induce ascitic fluid in mice. Cancer Res 1990;50:4915-7.
12. Korc M. Growth factors and pancreatic cancer. Int J Pancreatol 1991;9:87-91.
13. Glinsmann-Gibson BJ, Korc M. Regulation of transforming growth factor-alpha mRNA expression in T3M4 human pancreatic carcinoma cells. Pancreas 1991;6:142-9.
14. Estival A, Clerc P, Vaysse N, Tam JP, Clemente F. Decreased expression of transforming growth factor alpha during differentiation of human pancreatic cancer cells. Gastroenterology 1992;103:1851-9.
15. Gower WR, Risch RM, Codellas CV, Fabri PJ. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol 1994;30A:151-61.
16. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163:111-6.
17. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
18. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13: 565-9.
19. Chaudhry A, Öberg K. Transforming growth factor-alpha and epithelial growth factor receptor expression in neuroendocrine tumors of the digestive system: implications for an autocrine model. Diagn Oncol 1993;3:81-5.
20. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anti-cancer Res 1998;18:4613-9.
21. Modjtahedi HI, Eccles S, Sandle J, Box G, Titley J, Dean C. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 1994;54:1695-701.
22. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an antiepidermal growth factor receptor monoclonal antibody in the human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-905.
23. Mendelsohn J. Potential clinical applications of anti-EGF receptor monoclonal antibodies. In: Furth M, Greaves M, editors. Cancer cells. New York: Cold Spring Harbor Press, 1989:359-62.
24. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-7.
25. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Nat Acad Sci USA 1983;80:1337-41.
26. Sato JD, Kawanoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibody to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-29.
27. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-9.
28. Mendelsohn I, Masui H, Goldenberg A. Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway. Trans Assoc Am Physicians 1987;100:173-8.
29. Arteaga CL, Coronado E, Osborne CK. Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 1988;2:1064-9.
30. Ennis BW, Valverius EM, Lippman ME, Bellot F, Kris R., Schlessinger J, et al. Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and non-malignant human mammary epithelial cells. Mol Endocrinol 1989;3: 1830-8.
31. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor-α. Cancer Res 1991;51:2780-5.
32. Karnes WEJ, Walsh JH, Wu SV, Kim RS, Martin MG, Wong H, et al. Autocrine stimulation of EGF receptors by TGF-alpha regulates autonomous proliferation of human colon cancer cells. Gastroenterology 1992;102:474-85.
33. Masui H, Kawamoto T, Sato JD, Wolf B, Sato GH, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies. Cancer Res 1984;44:1002-7.
34. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin J Clin Invest 1995;95:1897-905.
35. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
36. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher H, et al. The biological effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother 1997;19:419-27.
37. Prewett M, Rothman M., Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998;4:2957-66.
38. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H., Eve BY, Hicklin DJ, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65.
39. Fan Z, Masui H, Atlas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibody. Cancer Res 1993;53:4322-8.
40. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, et al. J. Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.
41. Prewett M, Rockwell P, Rose C, Goldstein NI. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cis-platin. Int J Oncol 1996;9:217-24.
42. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;9:1935-40.
43. Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, et al. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin Cancer Res 1995;1:161-7.
44. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
45. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Metastasis Rev 1993;12:287-301.
46. Perez-Soler R, Donata NJ, Zhang HZ, Shin DM, Brewer HM, Rosenblum MG, et al. Phase I study of anti-epidermal growth factor receptor monoclonal antibody RG 83852 in patients with non-small lung cancer. J Clin Oncol 1994;12: 730-9.
47. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996;88:1770-6.
48. Bruns CJ, Portera CA, Tsan R, Hicklin DJ, Radinsky R. Regression of human pancreatic carcinoma growing orthotopically in athymic nude mice by blockade of epidermal growth factor receptor (EGF-R) signaling in combination with Gemcitabine. Proceedings of the 90th annual meeting of the American Association for Cancer Research; 1999 April 10-14; Philadelphia: Proceedings of the American Association for Cancer Research, 1999.
49. Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA Rutherford PG, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996;14:243-7.
50. Wu X, Rubin M, Fan Z, DeBlasio, T, Soos T, Koff A, et al. Involvement of p27KIP1 in G1 arrest mediation by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12:1397-403.
51. Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 1997;3:1943-8.
52. Chou J, Fan Z, Koff A, Mendelsohn J. EGF receptor blockade induces reversible growth arrest and changes in proteins that regulate the cell cycle in human mammary epithelial cells. Proceedings of the 87th annual meeting of the American Association for Cancer Research, 1996 March 30-April 2; Washington, DC: Proceedings of the American Association for Cancer Research, 1996.
53. Petit AMV, Rak J, Hung M, Rockwell P, Goldstein N, Fendley B, et al. Neutralizing antibodies EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production in tumor cells in vitro and in vivo: angiogenic implications for transduction therapy of solid tumors. Am J Pathol 1997;151: 1523-30.
54. Ezekiel MP, Bonner JA, Robert F, Meredith RF, Spencer SA, LoBuglio AF, et al. Phase I trial of chimerized anti-epidermal growth factor receptor antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proceedings of the 35th annual meeting of the American Association for Clinical Oncology, 1999 May 15-18; Atlanta: Proceedings of the American Association of Clinical Oncology, 1999.
55. Mendelsohn J, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, et al. A phase I study of chimerized anti-epidermal growth factor receptor monoclonal antibody, C225, in combination with cisplatin in patients with recurrent head and neck squamous cell carcinoma. Proceedings of the 35th annual meeting of the American Association for Clinical Oncology, May 15-18, 1999; Atlanta: Proceedings of the American Association of Clinical Oncology, 1999.